The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis

Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries

Am J Respir Crit Care Med.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C

doi: 10.1164/rccm.

CoughTuberculosis

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.

Lancet Respir Med.

Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, Te Riele J, Mastrapa B, Streicher EM, Dolby T, Abdallah AM, Ben-Rached F, Simpson J, Smith L, Gumbo T1, van Helden P, Sirgel FA, McNerney R, Theron G, Pain A, Clark TG, Warren RM

doi: 10.1016/

RECOMMENDED

Tuberculosis

Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lancet.

Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakadis P, Lange C, Menzies D, Migliori GB, Pape JW, Palmero D, Baghei P, Tabarsi P, Viiklepp P, Vilbrun S, Walsh J, Marks SM

doi: 10.1016/S0140-6736(20)31316-7.

RECOMMENDED

Tuberculosis

Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling

Lancet Infect Dis.

Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ

doi: 10.1016/S1473-3099(19)30307-X.

Tuberculosis

Bedaquiline or delamanid for rifampin-resistant tuberculosis?

Lancet Respir Med.

Lessem E, Cox V, Furin J

RECOMMENDED

Tuberculosis

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

Lancet Respir Med.

von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R

doi: 10.1016/S2213-2600(18)30426-0.

RECOMMENDED

Tuberculosis

Management of drug-resistant tuberculosis

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet.

Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR Jr

doi: 10.1016/S0140-6736(19)31882-3.

RECOMMENDED

Respiratory Tract Infection

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

★ 2 Recommended by Dr Martin Frey, Faculty Member

JAMA.

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC

doi: 10.1001/jama.2020.12839.

RECOMMENDED

Tuberculosis

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med.

Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017.

doi: 10.1016/S2213-2600(20)30047-3.

Related content

Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.

Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis

Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling

Bedaquiline or delamanid for rifampin-resistant tuberculosis?

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

Management of drug-resistant tuberculosis

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis